Phoenix, AZ -- April 27, 2017 --
InvestorsHub NewsWire -- NOHO, Inc. (OTC PINK: DRNK), a Wyoming
corporation (the “Company”), announced the following:
The Company has signed a letter of intent with DMR Biologic,
LLC, of Schonfield, Wisconsin, to acquire the rights to market and
sell its homeopathic OTC drug registered with the FDA.
This new formulation is taken via a patented, gel-based delivery
method contained in a small stick pack. The product is taken
sublingually (under the tongue), offering fast and
effective relief from Hangover pain and headache. In
bypassing the digestive system, the product is absorbed much faster
than liquid or pill-based formulas and has no contraindicated drug
interactions. The product’s effectiveness is confirmed by
multiple Double-blind/Placebo controlled clinical trials.
Developed as a drug to treat migraine headaches, under the proposed
deal, NOHO would have exclusive rights to the product in the
Hangover market and register the new brand with the FDA and obtain
a National Drug Code number. The proposed terms also include
distribution for a re-branded migraine product which NOHO would
market and sell through its new distributor, BNG Enterprises.
David Mersky, NOHO's CEO stated, "In keeping with our strategy
of pursuing undervalued assets like our 2oz Shot and Gold can
products when we came into NOHO, we have once again found a great
opportunity to bring an FDA compliant product to the Hangover
market. As an OTC drug, this new formulation will make NOHO
the market leader in the Hangover space, as none of the competition
has clinically tested data to be able to make specific drug
claims.” Negotiations also involve NOHO working to re-launch
a new iteration of the original migraine drug, called
Lipigesic. Mersky continued, “I believe this is a great
product that wasn’t properly packaged and didn’t have the
appropriate marketing to support it. The test results are
terrific and the migraine market is huge at around 50 million
people. We’re really good at identifying these hidden gems
that require a dust-off and some re-branding. All the time,
hard work and cost of the trials and FDA registration is already
done.”
In addition to the current formulation, the parties are
discussing a hemp infused product for NOHO to bring to
market. “We have identified a path to infuse Hemp, as a legal
food product, into the formula. A Hemp-infused Hangover drug
will fly off the shelves through our targeted distribution in smoke
shops and vape stores, said NOHO’s CEO, David Mersky.
For additional information on NOHO please visit www.nohodrink.com and our full
product site at www.imbutek.com and at
www.instagram.com/nohodrink, as well as at
www.twitter.com/nohodrink
Cautionary Note
Regarding Forward-Looking Statements.
This press release contains statements that
constitute forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as
amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or
current expectations of the Noho, Inc. (the “Company”), its
directors or its officers with respect to, among other things:
(i) financing plans; (ii) trends affecting its financial
condition or results of operations; (iii) growth strategy and
operating strategy. The words “may,” “would,” “will,” “expect,”
“estimate,” “can,” “believe,” “potential” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are
beyond the Company’s ability to control, and actual results may
differ materially from those projected in the forward
looking statements as a result of various factors. You should
not place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors,
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.